Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.38. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ACAD | YMAG | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $29.41 | $15.98 |
52-Week Low | $20.06 | $10.76 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.58, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.07 to $0.40 per share. News highlights ongoing distribution announcements and analysis of its option income strategy, though key financial ratios are not provided in the data.
The outlook hinges on YMAG's ability to sustain high distributions through its option strategy, but earnings volatility in underlying holdings poses a risk to NAV stability. Investor sentiment is mixed, with some analysts viewing it as a tactical buy in rangebound markets, while others caution on compounded decay across its seven underlying ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
